The Epigenetics of Drug Development and Cholesterol Levels

Epigenetic Drug Improves Cholesterol Levels

Results from a Phase II trial of an epigenetic therapy for cardiovascular disease show promise.

By Edyta Zielinska | August 28, 2012

Excerpt: “Resverlogix’s drug targets bromodomain proteins, which detect epigenetic modifications on histone proteins and recruits additional proteins to the site. As a result, the cells produce more Apo-A1, the main component of HDL, which helps remove atherosclerotic plaques already formed.”

My comment:

Isn’t the diet-responsive and presumably exercise- and pheromone-responsive hypothalamic neurogenic niche most likely to be involved in the cause and effect regulation of HDL via nutrient chemical-dependent epigenetic effects on gonadotropin releasing hormone?  If so, the epigenetic “tweaking” of immense gene networks that solve problems through the exchange and the selective cancellation and modification of signals will almost no doubt be accompanied by unanticipated side effects that could be more important to health than raising HDL.

About James V. Kohl 1307 Articles
James Vaughn Kohl was the first to accurately conceptualize human pheromones, and began presenting his findings to the scientific community in 1992. He continues to present to, and publish for, diverse scientific and lay audiences, while constantly monitoring the scientific presses for new information that is relevant to the development of his initial and ongoing conceptualization of human pheromones. Recently, Kohl integrated scientific evidence that pinpoints the evolved neurophysiological mechanism that links olfactory/pheromonal input to genes in hormone-secreting cells of tissue in a specific area of the brain that is primarily involved in the sensory integration of olfactory and visual input, and in the development of human sexual preferences. His award-winning 2007 article/book chapter on multisensory integration: The Mind’s Eyes: Human pheromones, neuroscience, and male sexual preferences followed an award winning 2001 publication: Human pheromones: integrating neuroendocrinology and ethology, which was coauthored by disinguished researchers from Vienna. Rarely do researchers win awards in multiple disciplines, but Kohl’s 2001 award was for neuroscience, and his 2007 “Reiss Theory” award was for social science. Kohl has worked as a medical laboratory scientist since 1974, and he has devoted more than twenty-five years to researching the relationship between the sense of smell and the development of human sexual preferences. Unlike many researchers who work with non-human subjects, medical laboratory scientists use the latest technology from many scientific disciplines to perform a variety of specialized diagnostic medical testing on people. James V. Kohl is certified with: * American Society for Clinical Pathology * American Medical Technologists James V. Kohl is a member of: * Society for Neuroscience * Society for Behavioral Neuroendocrinology * Association for Chemoreception Sciences * Society for the Scientific Study of Sexuality * International Society for Human Ethology * American Society for Clinical Laboratory Science * Mensa, the international high IQ society